|
Name |
Antimycin A4
|
Molecular Formula | C25H34N2O9 | |
IUPAC Name* |
[8-butyl-3-[(3-formamido-2-hydroxybenzoyl)amino]-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] butanoate
|
|
SMILES |
CCCCC1C(C(OC(=O)C(C(OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CCC
|
|
InChI |
InChI=1S/C25H34N2O9/c1-5-7-10-17-22(36-19(29)9-6-2)15(4)35-25(33)20(14(3)34-24(17)32)27-23(31)16-11-8-12-18(21(16)30)26-13-28/h8,11-15,17,20,22,30H,5-7,9-10H2,1-4H3,(H,26,28)(H,27,31)
|
|
InChIKey |
GYANSQKXOLFAFP-UHFFFAOYSA-N
|
|
Synonyms |
Antimycin A4; 27220-59-3; Antimycin A4 (7CI,9CI); 8-Butyl-3-(3-formamido-2-hydroxybenzamido)-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl butyrate; [8-butyl-3-[(3-formamido-2-hydroxybenzoyl)amino]-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] butanoate; EINECS 248-343-7; UNII-8X60D5011V; Butyric acid, N-ester with N-(7-butyl-8-hydroxy-4,9-dimethyl-2,6-dioxo-1,6-dioxonan-3-yl)-3-formamidosalicylamide; 8X60D5011V; J-016700
|
|
CAS | 27220-59-3 | |
PubChem CID | 3084472 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 506.5 | ALogp: | 3.8 |
HBD: | 3 | HBA: | 9 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 157.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 36 | QED Weighted: | 0.187 |
Caco-2 Permeability: | -4.918 | MDCK Permeability: | 0.00007120 |
Pgp-inhibitor: | 0.476 | Pgp-substrate: | 0.022 |
Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.014 |
30% Bioavailability (F30%): | 0.99 |
Blood-Brain-Barrier Penetration (BBB): | 0.985 | Plasma Protein Binding (PPB): | 76.34% |
Volume Distribution (VD): | 0.594 | Fu: | 18.14% |
CYP1A2-inhibitor: | 0.112 | CYP1A2-substrate: | 0.105 |
CYP2C19-inhibitor: | 0.281 | CYP2C19-substrate: | 0.107 |
CYP2C9-inhibitor: | 0.539 | CYP2C9-substrate: | 0.929 |
CYP2D6-inhibitor: | 0.145 | CYP2D6-substrate: | 0.229 |
CYP3A4-inhibitor: | 0.892 | CYP3A4-substrate: | 0.164 |
Clearance (CL): | 2.477 | Half-life (T1/2): | 0.616 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.547 |
Drug-inuced Liver Injury (DILI): | 0.916 | AMES Toxicity: | 0.009 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.046 | Carcinogencity: | 0.116 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.017 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001502 | 0.924 | D07IPB | 0.269 | ||||
ENC001023 | 0.850 | D00OAY | 0.255 | ||||
ENC000483 | 0.805 | D0NP1J | 0.252 | ||||
ENC000878 | 0.287 | D06TQZ | 0.244 | ||||
ENC004061 | 0.279 | D0A0JH | 0.236 | ||||
ENC003353 | 0.253 | D0HD9K | 0.235 | ||||
ENC003952 | 0.244 | D09ELP | 0.234 | ||||
ENC000544 | 0.244 | D0T5XN | 0.230 | ||||
ENC003052 | 0.243 | D0R2KJ | 0.226 | ||||
ENC002794 | 0.242 | D0Q2AT | 0.226 |